1	Population-scale analysis of common and rare genetic variation
2	associated with hearing loss in adults
3	
4	Kavita Praveen ¹ , Lee Dobbyn ¹ , Lauren Gurski ¹ , Ariane H. Ayer ¹ , Jeffrey Staples ¹ , Shawn
5	Mishra ² , Yu Bai ² , Alexandra Kaufman ² , Arden Moscati ¹ , Christian Benner ¹ , Esteban Chen ¹ ,
6	Siying Chen ¹ , Alexander Popov ¹ , Janell Smith ² , GHS-REGN DiscovEHR collaboration [*] ,
7	Regeneron Genetics Center*, Decibel-REGN collaboration*, Olle Melander ^{3,4} , Marcus Jones ¹ ,
8	Jonathan Marchini ¹ , Suganthi Balasubramanian ¹ , Brian Zambrowicz ² , Meghan Drummond ² , Aris
9	Baras ¹ , Goncalo R. Abecasis ¹ , Manuel A. Ferreira ¹ , Eli A. Stahl ¹ , Giovanni Coppola ¹
10	
11	From:
12	¹ Regeneron Genetics Center, Tarrytown, NY 10591, USA.
13	² Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.
14	³ Lund University, Department of Clinical Sciences Malmö, Malmö, Sweden.
15	⁴ Skåne University Hospital, Department of Emergency and Internal Medicine, Malmö, Sweden.
16	*A complete list of contributing authors to the Regeneron Genetics Center, GHS-RGC DiscovEHR
17	Collaboration and the Decibel-REGN Collaborations is provided in the Supplementary Appendix.
18	Correspondence to giovanni.coppola@regeneron.com.

19 ABSTRACT

20 Understanding the genetic underpinnings of disabling hearing loss, which affects ~466 million people worldwide, can provide avenues for new therapeutic target development. We 21 22 performed a genome-wide association meta-analysis of hearing loss with 125,749 cases and 23 469,497 controls across five cohorts, including UK Biobank, Geisinger DiscovEHR, the Malmö 24 Diet and Cancer Study, Mount Sinai's BioMe Personalized Medicine Cohort, and FinnGen. We 25 identified 53 loci affecting hearing loss risk, 15 of which are novel, including common coding 26 variants in COL9A3 and TMPRSS3. Through exome-sequencing of 108,415 cases and 329,581 27 controls from the same cohorts, we identified hearing loss associations with burden of rare coding 28 variants in FSCN2 (odds ratio [OR] = 1.14, $P = 1.9 \times 10^{-15}$) and burden of predicted loss-of-29 function variants in *KLHDC7B* (OR = 2.14, $P = 5.2 \times 10^{-30}$). We also observed single-variant and 30 gene-burden associations with 11 genes known to cause Mendelian forms of hearing loss, 31 including an increased risk in heterozygous carriers of mutations in the autosomal recessive 32 hearing loss genes GJB2 (Gly12fs; OR = 1.21, $P = 4.2 \times 10^{-11}$) and SLC26A5 (gene burden; OR = 1.96, $P = 2.8 \times 10^{-17}$). Our results suggest that loss of KLHDC7B function increases risk for hearing 33 34 loss, and show that Mendelian hearing loss genes contribute to the burden of hearing loss in the 35 adult population, suggesting a shared etiology between common and rare forms of hearing loss. This work illustrates the potential of large-scale exome sequencing to elucidate the genetic 36 37 architecture of common traits in which risk is modulated by both common and rare variation.

39 INTRODUCTION

40 The loss of hearing can have a debilitating impact on quality of life, requiring major adjustments to day-to-day activities. Significant comorbidities are also associated with hearing 41 42 loss including social isolation, depression, cognitive impairment, and dementia, which further 43 deteriorate quality of life¹. Disabling hearing loss is common, with ~466 million people affected 44 worldwide (World Health Organization: https://www.who.int/health-topics/hearing-loss). While 45 existing technologies – such as hearing aids and cochlear implants – can ameliorate hearing loss, their use is limited by barriers to access, including cost, health policies and regulations, and social 46 stigma associated with device use². Furthermore, while these assistive devices typically provide 47 48 some benefit, they do not address the chief complaint associated with acquired hearing loss: lack 49 of hearing clarity, particularly in social and work environments (https://www.hearingloss.org/hlaa-50 pfdd/). The Lancet Commission on dementia prevention, intervention and care has identified 51 untreated hearing loss in middle age as the top modifiable risk factor for dementia, but it is 52 estimated that 67-86% of adults who may benefit from hearing aids do not use them^{1,3}. These 53 challenges, combined with a lack of therapeutics to stop or slow hearing loss progression, have contributed to its status as a growing global health issue. Novel therapies based on genetic 54 55 evidence, therefore, will be crucial in addressing this unmet need.

Hearing loss affects individuals of all ages, but its prevalence increases with age. Approximately 1-2/1,000 babies are born with hearing loss⁴. Mutations in over 150 genes (hereditaryhearingloss.com) account for over 50% of the cases. While autosomal recessive hearing loss is generally pre-lingual and non-progressive, autosomal dominant forms are mostly postlingual (including adult onset) and progressive. The prevalence of hearing loss increases to 2.8/1,000 in primary school-age children and 3.5/1,000 in adolescents^{4.5}. The National Institute on

Deafness and other Communication Diseases calculates that by the age of 45 ~2% of individuals have a disabling hearing loss, and this number increases to 50% in individuals over the age of 75. This increase in prevalence with age reflects a combination of late-onset hearing loss mutations, the cumulative effects of environmental factors such as exposure to noise and ototoxic drugs and, in aging individuals, the degenerative effects of age on the cochlea. These genetic and environmental insults primarily damage the structures of the inner ear, resulting in sensorineural hearing loss^{6,7}.

Heritability estimates for age-related hearing loss range as high as 36 and 70%⁸⁻¹² suggesting that genetics, along with environmental factors, play a significant role in determining an individual's risk for developing hearing loss. Genome-wide association studies (GWAS) of hearing loss in adults have identified 61 common variant loci associated with the trait in Europeans¹³⁻¹⁸. While the majority of these studies have established a common variant contribution to adult hearing loss, there are few reports addressing rare and low-frequency variant contribution¹⁹.

76 Recently, Ivarsdottir et al¹⁸ published association results with hearing loss on ~50K Icelandic individuals with whole-genome sequence and ~50K individuals from UKB with exome 77 78 sequence data, with imputation of larger samples into these variant sets. We have now expanded 79 the rare variant analysis to exome-sequences from ~295K individuals in UKB and ~143K 80 individuals from three other datasets. Here, we report findings from genome- and exome-wide 81 association meta analyses with a total of 125,749 cases and 469,497 controls. Our analyses have 82 identified 15 novel susceptibility loci and 15 rare variant associations that provide novel insights 83 into the biology of hearing loss in adults.

85 **RESULTS**

86 To study common variants, we performed association meta-analyses using genotyping and 87 imputation across five cohorts: Geisinger DiscovEHR study (GHS), the Malmö Diet and Cancer 88 study from Malmö, Sweden (MALMO), Mount Sinai's BioMe Personalized Medicine Cohort 89 from Mount Sinai Health System, New York (SINAI), UK Biobank (UKB) and an additional study 90 from Finland, FinnGen, for a total of 125,749 cases and 469,497 controls. To study rare and ultra-91 rare variants, we also generated exome sequence data and performed combined GWAS and 92 exome-wide association study (ExWAS) on a subset of 108,415 cases and 329,581 controls across 93 GHS, MALMO, SINAI, and UKB. Phenotypes were derived from ICD-10 diagnosis codes in 94 GHS, MALMO, SINAI and FinnGen, and combined self-report and ICD-10 codes in UKB (see 95 Methods and Supplementary Table 1 for details). Our genome-wide association analyses included 96 15,881,489 variants with frequency > 0.1% that were genotyped or imputed with r2 > 0.3 in at 97 least one study, and 2,923,124 coding or essential splice site variants with minor allele count at 98 least five from exome sequencing (111,588 of which overlapped with the imputed).

99

100 Novel common variant associations

101 We identified 53 independent loci harboring genome-wide significant ($P < 5 \times 10^{-8}$) 102 common (MAF $\ge 1\%$) variants associated with hearing loss (Figure 1A, Supplementary Table 2, 103 Supplementary Figure 1), 38 of which are shared with the previously reported 61 hearing loss-104 associated loci. We observed a genomic control lambda_GC = 1.36 but an LD score regression 105 intercept 1.054 (standard error 0.008), indicating that inflation was largely due to polygenic signal 106 for the hearing loss phenotype.

107 Among the lead variants at the 15 novel loci (Figure 1A, Table 1, Supplementary Figure 108 2) is rs117887149 that maps close to *GJB2* (Supplementary Figure 2H), which is a predominant 109 cause of congenital hearing loss. While majority of the lead variants in the novel loci lay in 110 intergenic or downstream/upstream regions of genes, at two loci they were within the introns of 111 the following genes: *KCTD10*, a member of the potassium channel tetramerization domain family 112 that is implicated in cardiac development^{20,21} and *MAP7D2*, an axonal cargo transport protein 113 predominantly expressed in the brain²².

114 Top variants at two other novel loci were missense changes and thus also implicate specific 115 genes: in COL9A3 (Arg103Trp; MAF = 0.066) and TMPRSS3 (Ala90Thr; MAF = 0.055). 116 Mutations in COL9A3, which is highly expressed in the ear, have been implicated in the autosomal 117 recessive Stickler syndrome, in which hearing loss is prominent²³, and tentatively in non-118 syndromic hearing loss^{24,25}. High-throughput mouse knockout characterization from the 119 International Mouse Phenotyping Consortium (IMPC) indicates that Col9a3-null mice also have 120 hearing loss²⁶. *TMPRSS3* is a type II membrane serine protease that localizes to the endoplasmic 121 reticulum and plasma membranes, and is expressed in hair cells and supporting cells in the organ 122 of Corti, the spiral ganglion, and the stria vascularis in the ear²⁷⁻²⁹. Mutations in *TMPRSS3* cause congenital and childhood-onset autosomal recessive hearing loss³⁰ but there is also evidence for 123 124 hearing deficits in heterozygous carriers¹⁸.

The number of associated variants at the 50 autosomal loci ranged from eight to 1,326. In order to assess the presence of multiple independent causal variants at each locus, we ran conditional analyses using GCTA-COJO³¹, which indicated the presence of secondary association signals (joint $P < 10^{-5}$) at eight loci (Supplementary Table 3). We also ran FINEMAP Bayesian causal variant inference³² to prioritize associated variants as credibly causal at thirty loci that were

130genome-wide significant in RGC data (excluding FinnGen). The COJO and FINEMAP methods131disagreed on the presence of single vs. multiple association signals within five loci, three of which132showed subthreshold $(10^{-5} < P < 10^{-4})$ secondary associations in COJO. FINEMAP prioritized ten133or fewer variants in top causal variant 95% credible sets for the top causal variant at eleven loci,134including single putatively causal variants at four loci (Supplementary Table 3): missense variants135in *CDH23* (Ala371Thr; rs143282422) and *KLHDC7B* (Val504Met; rs36062310), and intronic136variants in *CTBP2* (rs10901863) and *PAFAH1B1* (rs12938775).

137

138 Colocalization with GTEx eQTLs identifies candidate genes driving GWAS signals.

139 To identify genes for which expression regulation might drive the observed association 140 signals, we tested for colocalization of our hearing loss-associated loci with expression quantitative 141 trait loci (eQTL) data for 48 tissues from the Genotype-Tissue Expression (GTEx) project (see 142 URLs) using coloc2³³. Across all GTEx eQTL tissues tested, we identified 19 genes mapping to 143 15 loci with evidence (posterior probability of colocalization, PPH4 ≥ 0.5) for colocalization 144 between the hearing loss association and an eQTL signal, in at least one tissue (Supplementary 145 Table 4). Only two of the 15 loci with GWAS-eQTL overlap had multiple eQTL signals for more 146 than one gene (NUCKS1 and RAB29 in locus 1-4; ACADVL, DLG4, CTDNEP1 and CLDN7 in 147 locus 17-2) making it difficult to prioritize causal genes at these loci based on eQTL data. Since 148 GTEx did not include tissues from the ear, we used single-cell RNA sequencing data that were 149 generated in-house from mouse cochleae to check the expression of the 19 genes in the ear 150 (Supplementary Table 5). Thirteen of the 19 genes showed evidence of expression across 26 inner-151 ear cell-types and, of these, 12 were expressed in the hair cells. While the majority of genes showed 152 broad expression across the 26 cell types, we noted a subset that were specific to only a few,

including *CRIP3* in inner and outer hair cells, and *TCF19* in neurons and immune cells(Supplementary Tables 4 & 5).

155

156 Rare-variant association analysis identifies novel large-effect hearing loss variants in known

157 hearing loss genes.

158 We identified significant ($P < 5 \times 10^{-8}$) rare variant (MAF < 1%) associations in 25 genes, 159 15 of which had nonsynonymous variant or gene burden associations (Figure 1B, Table 2, Supplementary Tables 6 & 7). Five of the 15 genes also had significant common variant 160 161 associations within 1 Mb (KLHDC7B, SYNJ2, GJB2, EYA4, and CDH23). After conditioning on 162 independent common variants at each locus (Supplementary Tables 6, 7 & 8), the rare variant and 163 gene burdens remained associated with hearing loss (maximum conditional $P \le 3 \times 10^{-5}$) except 164 for the *CDH23* Asn1103Ser association (conditional P = 0.79). Of note, the lead common variant 165 in *CDH23* is also a missense (Ala371Thr) variant (MAF = 1.1%) and is pinpointed by FINEMAP 166 as the only causal variant at that locus with high confidence. Overall, our conditional analyses 167 suggest that rare variant association signals are usually independent of nearby common variant 168 associations.

169

170 Associations with Mendelian hearing loss genes

Of the 14 genes with independent, rare nonsynonymous and/or burden associations, 11 were previously identified as causes of Mendelian forms of hearing loss. These include associations with two genes (*GJB2* and *SLC26A5*) that cause recessive hearing loss, burden associations in seven genes (*MYO6*, *COCH*, *TECTA*, *SIX1*, *CEACAM16*, *POU4F3*, and *EYA4*) and single-variant associations in two genes (*TBC1D24* and *COL11A2*) that cause autosomal dominant

176 hearing loss (reviewed in Shearer et. al., 1999³⁴). In MYO6 and COCH, we also observed genome-177 wide significant single-variant associations of large effect size (MYO6 His246Arg, OR=30.7; 178 COCH Cys542Phe, OR=81.4; Supplementary Table 6). Both variants have previously been 179 characterized as pathogenic in family-based genetic analyses^{35,36}. Only a minority of variants 180 included in burden tests have been classified as pathogenic by ClinVar (Supplementary Table 9) 181 suggesting that our analysis has detected additional novel, risk-associated variants with variable 182 penetrance in Mendelian hearing loss genes. We also identified single-variant associations in two 183 genes that cause autosomal dominant hearing loss: TBC1D24 Asn307Ser, also recently reported 184 by Ivarsdottir et al¹⁸, was implicated as pathogenic in two unrelated families³⁷, and COL11A2 185 Phe80Ser, which has not yet been classified as pathogenic but is predicted deleterious, lies in a 186 domain (Laminin G-like/NC4) that harbors other mutations causing non-syndromic hearing loss³⁸. 187 We performed our analysis under an additive model, which assumes risk effects in 188 heterozygous carriers as well as homozygotes; therefore, it is not surprising to see that the majority

189 of Mendelian genes (9/11) identified can cause hearing loss in heterozygote carriers. However, we 190 also detect associations in two genes that have previously been implicated in recessive hearing 191 loss: GJB2 Gly12fs (OR = 1.21; $P = 4 \times 10^{-11}$), and SLC26A5 Leu46Pro (OR = 1.3; $P = 3 \times 10^{-14}$) 192 as well as the burden of SLC26A5 predicted loss-of-function (pLOF) and strict deleterious 193 missense variants (excluding Leu46Pro) (OR = 1.96; $P = 3 \times 10^{-17}$) (Figure 2). We also observed 194 a suggestive association with GJB2 Leu90Pro (OR = 1.51, $P = 4.4 \times 10^{-5}$), another known 195 pathogenic variant in recessive hearing loss. The associations persisted after excluding homozygous carriers and compound heterozygous carriers of rare, coding variants in these genes 196 197 (Supplementary Table 10), suggesting a previously unappreciated increase in risk for hearing loss 198 in heterozygous carriers of loss-of-function GJB2, and missense and pLOF SLC26A5 variants.

199

200 Rare variant associations in KLHDC7B, FSCN2, and SYNJ2

201 The most significant rare coding association in our analysis was the aggregate of 68 pLOF 202 variants (43 frameshift, 23 stop-gain and 2 stop-loss, (Supplementary Table 9)) in KLHDC7B 203 (Kelch-like domain containing 7B), with an approximately two-fold increase in risk for hearing 204 loss (OR = 2.14, $P = 5 \times 10^{-30}$). The main contributors to the gene burden were two frameshift 205 variants, Gly302fs and Lys181fs, that are predicted to truncate the protein near the start of the 206 Kelch domains. These variants were also significantly associated in single-variant tests (Figure 3), 207 and Gly302fs was recently reported in an analysis that included UKB¹⁸. The association with pLOF 208 variants remained significant after repeating the pLOF burden test conditioning on Gly302fs and 209 Lys181fs ($P = 8 \times 10^{-8}$; Supplementary Table 7). In addition, we observed a common (MAF = 4%) 210 missense variant (Val504Met) within the last Kelch domain of KLHDC7B associated with increased risk for hearing loss (OR = 1.14, $P = 4 \times 10^{-26}$). This variant was also prioritized as the 211 212 sole causal variant at this locus by FINEMAP (Supplementary Table 3).

213 We also identified rare coding associations in fascin actin-bundling protein 2 (FSCN2) and 214 synaptojanin 2 (SYNJ2) with increased risk for hearing loss, both of which were recently observed 215 in UKB¹⁸ (Figure 4). In FSCN2, an actin cross-linking protein³⁹⁻⁴¹, an aggregate of pLOF and 216 deleterious missense variants was associated with hearing loss, with majority of the carriers in the 217 burden having the His138Tyr variant. Conditioning on His138Tyr attenuated the significance of 218 the burden test ($P = 3 \times 10^{-6}$ after conditioning on His138Tyr; Supplementary Table 7) but did not 219 eliminate the signal, suggesting that other variants in FSCN2 may increase the risk for hearing 220 loss. Mice homozygous for loss-of-function mutations in Fscn2 present progressive hearing loss 221 starting at 3 weeks and near deafness by 24 weeks due to degeneration of the outer hair cells in the

222 cochlea⁴¹. In *SYNJ2*, we identified an association with a missense (Thr656Met)¹⁸ variant that lies 223 in the catalytic domain of this inositol polyphosphate 5-phosphatase⁴². Mice harboring 224 homozygous mutations in *Synj2* that are predicted to reduce protein levels or the 5-phosphatase 225 catalytic activity show progressive high-frequency hearing loss and a degeneration of hair cells 226 that is most profound in the outer hair cells^{43,44}.

227

228 GWAS/ExWAS supports a highly polygenic architecture of adult hearing loss.

229 Given that this is the largest sequencing study to date of adult hearing loss, and given the 230 presence of Mendelian hearing loss genes among our common and rare-variant associations, we 231 sought to explore the distribution of effect sizes across allele frequencies (Figure 5). Hearing loss-232 associated variants span the frequency spectrum and, while we observe a few rare variants of large 233 effect (e.g. COCH Cys542Phe and MYO6 His246Arg), we do not observe any common variants 234 of large effect. We further estimated phenotypic variance explained by the genetic data, or 235 heritability h_{Tot}^2 , using LD score regression (LDSC) partitioning into functional categories and stratifying by minor allele frequency^{45,46}. We estimated a total heritability (h²_{Tot}) of 0.089, with 236 contributions from common variation (h_{CV}^2 , MAF > 0.05) and low-frequency variation (h_{LFV}^2 , 237 238 $0.001 < MAF \le 0.05$) of 0.074 and 0.015, respectively (Supplementary Figure 3, Supplementary 239 Table 11). These results indicate that, while the bulk of SNP heritability is derived from common 240 variation, low-frequency variation contributes 16.8% of total SNP heritability.

241 **DISCUSSION**

242 We performed combined GWAS and ExWAS using exome sequencing data and identified 243 53 independent associations, of which 15 were novel. Novel associations included a missense lead 244 variant in TMPRSS3, a known cause of Mendelian hearing loss, adding to the tally of Mendelian 245 deafness genes (EYA4, CDH23, TRIOBP) showing common coding-variant associations with 246 hearing loss in adult humans. We also identified coding variant/gene burden associations with 15 247 genes through exome sequencing. We estimated that low-frequency variation contributes a non-248 negligible portion (16.8%) of SNP heritability for adult hearing loss, consistent with a highly 249 polygenic genetic architecture with rare, low-frequency and common genetic variation for adult 250 hearing loss, and where variants of large effect would be subject to purifying selection.

251 Notably, the majority of genes implicated by rare-variant and burden associations are 252 already known to cause Mendelian forms of hearing loss; however, the odds ratios for these associations are wide-ranging. At the lower end of the effect spectrum are single-variant 253 254 associations in GJB2 and SLC26A5, with ORs close to typical for low-frequency GWAS findings 255 (1.2-1.3), followed by COL11A2 (2.2-7) and, at the highest end of the distribution, COCH and 256 MYO6 (31-81). COCH Cys542Phe and MYO6 His246Arg are known pathogenic variants, and 257 consistent with this, we see almost all carriers presenting hearing loss. The two control carriers for 258 each variant (Supplementary Table 6) could be explained by imperfect ascertainment of the 259 phenotype or, as these mutations cause late-onset and progressive hearing loss, could also reflect 260 a difference in expressivity. While some dilution of the effect sizes may be expected when working 261 with self-reported as opposed to objective measures of hearing loss, the broad range in ORs that 262 we observe suggests that for several of these Mendelian hearing loss genes we are identifying 263 carriers with incompletely penetrant, risk-increasing variants. These results are consistent with the

hypothesis that there is a continuum between Mendelian and common forms of hearing loss with
the same genes harboring mutations 'causal' for the former, and risk-increasing for the latter.
Furthermore, compared to epidemiological risk factors for common hearing loss, including noise
exposure (OR~1.5-3⁴⁷), odds ratios of low-frequency and rare genetic factors may be large enough
to provide mechanistic insights and to have implications for precision medicine.

269 Ultimately, to understand the biology of hearing loss and develop testable hypotheses from 270 our association results, we need to identify the genes driving the observed associations at each 271 locus. For common variants, we note the high resolution of FINEMAP to prioritize causal variants 272 in several loci, including pinpointing single variants in four genes, three of which are related to 273 hearing loss (CDH23), hearing function (CTBP2), or have significant rare variant associations with 274 hearing loss (*KLHDC7B*). While FINEMAP helps prioritize variants, the gene that is impacted by 275 those variants is not necessarily obvious, so we looked for colocalization with GTEx eQTL data 276 and identified 19 genes whose expression may influence hearing loss risk (Supplementary Table 277 4). Analysis of single-cell expression data from mouse ears showed that 13 of the 19 genes are 278 expressed in the ear. Of note, among these are LMO7 and SPTBN1 (BetaII-spectrin). Both genes 279 code for components of the cuticular plate in the hair cells of the ear and knockout mice for either 280 gene develop hearing loss^{48,49}. *LMO7* colocalizes with eQTLs for the gene in GTEx skeletal muscle 281 and SPTBN1 in thyroid tissue, such that decreased expression of these genes is correlated with 282 increased risk for hearing loss in humans.

One of the most compelling ways in which human genetics can establish a role for a gene in disease is when a diverse set of rare nonsynonymous or loss-of-function variants in the same gene show consistent association with disease. Coding variant and gene burden associations that we identified included associations with known pathogenic (e.g. in *MYO6* and *COCH*) and novel

287 variants (COL11A2 Phe80Ser), in genes that can cause autosomal dominant Mendelian hearing 288 loss. We also identified variants and genes that cause recessive hearing loss (GJB2 Gly12fs and 289 SLC26A5 pLOF+strict deleterious missense mutations), associated with increased risk (OR~1.2-290 1.3) for hearing loss in heterozygous carriers. Missense mutations in GJB2 can cause dominant, 291 syndromic hearing loss⁵⁰ but loss-of-function mutations, including Gly12fs, cause recessive non-292 syndromic hearing loss⁵¹⁻⁵³. Consistent with our findings, studies have detected hearing deficiency 293 at high frequencies and a possibly more prominent effect in female adult heterozygous carriers of 294 Gly12fs⁵³⁻⁵⁵. Mutations in *SLC26A5* cause recessive hearing loss in humans⁵⁶ and mice 295 homozygous for Slc26a5 null mutations develop hearing loss as early as 5-7 weeks of age^{57} . 296 *Slc26a5* heterozygous null mice have a hearing deficiency that is intermediate between the controls 297 and knockouts. While we cannot rule out the possibility of compound heterozygosity with 298 variation in regulatory/promoter regions in heterozygous carriers, our results offer the possibility 299 that heterozygous carriers of loss-of-function variants in GJB2 and SLC26A5 may also have 300 increased risk for adult-onset hearing loss.

301 Three of the 15 coding and burden associations were in genes that have not previously been 302 implicated in Mendelian hearing loss in humans: KLHDC7B, FSCN2, and SYNJ2. In KLHDC7B, 303 we confirmed a previously reported association of the common Val504Met and a rare frameshift 304 variant with increased risk for hearing loss^{18,58}, and identified associations of increased risk with a 305 burden of additional pLOF variants. While the biological effect of the missense is difficult to 306 interpret, the association of putative LOFs with increased risk for hearing loss suggests that loss 307 of KLHDC7B function is deleterious for hearing function. Based on the smaller effect of 308 Val504Met (OR = 1.14) compared to the pLOF burden (OR=2.14), we would hypothesize that this 309 more common missense (MAF = 4%) is a hypomorph. *KLHDC7B* (Kelch-like domain containing

310 7B) is a relatively understudied gene; it has been characterized as a 594-amino-acid protein 311 containing a Kelch domain that is hypermethylated and upregulated in breast cancer cell lines and 312 may influence cell proliferation in MCF-7 cells lines^{59,60}. In the mouse ear, RNAseq expression 313 profiling⁶¹ and our real-time PCR data (Supplementary Figure 4) show *Klhdc7B* expression in the cochlea with enrichment in the outer hair cells⁶². Consistent with the hypothesis from our genetic 314 315 findings that loss of KLHDC7B function increases risk for hearing loss, initial characterization of 316 *Klhdc7B* null mice by IMPC showed that homozygous carriers have hearing loss²⁶. Mouse models 317 *Fscn2* and *Synj2* also develop hearing loss^{41,43,44}. Based on our association results, it would also be 318 interesting to test heterozygous null Klhdc7b, Fscn2, and Synj2 animals for increased susceptibility 319 to hearing loss with age or environmental insults such as noise-exposure.

320 We recognize that our study has several limitations. Our phenotype includes (in UKB) self-321 reported hearing loss among adults, which is likely to be a heterogeneous mix of early-onset, late-322 onset, age-related, as well as hearing loss due to environmental insults. In general, greater 323 phenotype precision, including environmental exposure measures, should help future genetic 324 analyses of adult hearing loss. We note that our colocalization analyses utilized GTEx eQTL data 325 across tissues not including ear expression data. Given the high degree of sharing of genetic 326 regulation of expression across tissues^{63,64}, the results are likely to point to the causal genes in many 327 instances. eQTL data for ear cell types should help with the interpretation of genetic analyses of 328 adult hearing loss.

In summary, this work contributes to connecting the two ends of the genetic architecture of hearing loss by detecting a common signal in genes known to cause hearing loss in Mendelian fashion and by detecting an additive signal (i.e. increased risk in heterozygous carriers) in genes known to cause autosomal recessive hearing loss. This latter finding also connects young- and

- adult-onset hearing loss in a single phenotypic spectrum with complex genetic underpinnings,
- including contributions from rare and common variation.

335 METHODS

336 Participating cohorts and phenotype data

337 We performed meta-analysis for hearing loss on a total of 125,749 cases and 469,495 338 controls of European ancestry from the following cohorts: United Kingdom Biobank (UKB)65, the 339 MyCode Community Health Initiative cohort from Geisinger Health System (GHS)⁶⁶, the Mount 340 Sinai Biome cohort (SINAI) (see URLs), the Malmö Diet and Cancer study (MALMO)⁶⁷, and 341 FinnGen R3 (URLs). Hearing loss case-control status in GHS, MALMO and SINAI was defined 342 using ICD-10 code diagnoses from the EHR. Cases were individuals with ICD10 H90.3-H90.8, 343 H91.1or H91.9 diagnoses. Controls were individuals who did not meet the case criteria and did 344 not have a diagnosis for ICD-10 Q16 (congenital malformations of ear causing hearing 345 impairment) or ICD-10 H93.1 (tinnitus). In UKB the phenotype was defined using ICD-10 codes 346 as above or by self-reported hearing loss or complete deafness on the touchscreen questionnaire 347 (Field IDs: 2247 and 2257). Controls in UKB were individuals who did not have an ICD-10 348 diagnosis for hearing loss or tinnitus and did not self-report hearing loss, deafness or tinnitus (Field 349 IDs: 4803 and non-cancer illness code 1597). The FinnGen analysis used was 350 finngen r3 H8 CONSENHEARINGLOSS, conductive or sensorineural hearing loss defined by 351 ICD10 codes H90[.0-8], versus controls excluding other ear disorders (H91-H95). Further details 352 are given in the Supplementary Note.

353

354 Genetic data and association analyses

High-coverage whole-exome sequencing was performed at the Regeneron Genetics Center as previously described^{68,69}. For SINAI and MALMO, DNA from participants was genotyped on the Global Screening Array (GSA), and for GHS genotyping was done on either the Illumina OmniExpress Exome (OMNI) or GSA array; the datasets (stratified by array for GHS) were

359 imputed to the TOPMed (GHS) or HRC (MALMO and SINAI) reference panels using the 360 University of Michigan Imputation Server or the TOPMed Imputation Server (URLs). Additional 361 details are given in the Supplementary Note. We tested for association with hearing loss genetic 362 variants or their gene burdens using REGENIE v1.0.4370. Analyses were adjusted for age, age2, 363 sex, an age-by-sex interaction term, experimental batch-related covariates, and genetic principal 364 components. Cohort-specific statistical analysis details are provided in the Supplementary Note. 365 Results across cohorts were pooled using inverse-variance weighted meta-analysis.

366

367

Fine mapping and follow-on genetic analyses.

368 We defined genome-wide significant loci in our analysis by linkage disequilibrium ($r^2 > r^2$) 369 0.1) with lead variants. We defined previously associated loci by their index variants reported in 370 previous hearing loss GWAS^{13-17,58,71-75}, and excluded 1 Mb regions surrounding them in the 371 identification of novel loci in our analysis. LD score (LDSC) regression⁷⁶ was used to assess 372 inflation (LDSC intercept) accounting for polygenic signal. Power calculations determined 373 genotype relative risks (GRRs) providing 80 and 50 percent power given specified risk allele 374 frequencies (RAFs, from 10⁻⁶ to 1) and the numbers of cases and controls in our meta-analysis. 375 Fine mapping analyses included forward stepwise conditional analyses carried out in every locus 376 with GCTA-COJO using a UK Biobank subsample LD reference panel, with independent associations determined using a joint P-value threshold of 1×10^{-5} and r^2 cutoff of 0.9, and 377 378 FINEMAP³³ Bayesian causal variant inference, using LD from available individual level data.

379 For genes whose cis regions overlapped genome-wide significant hearing loss loci, 380 coloc275,76 was used to assess evidence for colocalization between our hearing loss GWAS and 381 GTEx (release v8) cis-eQTL data derived from 48 tissues (URLs), using GWAS and eQTL 382 summary statistics for all common (MAF ≥ 0.01) variants within each gene's cis-region. Genes

with posterior probability of colocalization $H4 \ge 0.5$ were determined as having evidence for colocalization, and were visually inspected in eQTL+GWAS regional association plots (Supplementary Figure 5).

Conditional analyses were performed for each cohort using REGENIE's Firth-corrected logistic regression and the resulting summary statistics were meta-analyzed as described above. Rare variant association analyses conditional on the common variant signal were carried out for four loci with both common (MAF \ge 0.01) and single rare variant (MAF < 0.01) genome-wide significant signals, by including as covariates the dosages of variants identified in fine mapping analyses. Burden analyses conditional on rare variants were carried out for five genes with significant single rare variant and burden associations.

Assessment of heterozygous effects used association analyses excluding homozygotes as well as individuals carrying pairs of exome sequenced variants (MAF < 2% and MAC > 1) that were called as compound heterozygous mutations (CHMs) or potential CMHs (i.e. unknown phase). CHMs were called by SHAPEIT4 phasing of merged genotype and exome data with scaffolds based on inferred close relatives^{77,78}.

Heritability derived from variants partitioned into seven functional categories (codingsynonymous, coding-nonsynonymous, 5-prime-UTR, 3-prime-UTR, splice site, intronic, intergenic) with each category further stratified into a low frequency ($0.001 < MAF \le 0.05$) and common (MAF > 0.05) minor allele frequency bin as in stratified LD score regression was estimated using LD score regression (LDSC) of hearing loss association statistics on LD scores. LD scores were generated from a reference panel of N = 10,000 random UK Biobank Europeanancestry samples' merged imputed and exome data.

406 Single-Cell RNA Sequencing and Analysis

407	All protocols were approved by the Institutional Animal Care and Use Committee in
408	accordance with the Regeneron's Institutional Animal Care and Use Committee (IACUC).
409	Cochlea and utricles from C57BL/6 mice at post-natal day 7 were micro-dissected and dissociated.
410	Suspensions of 200 cells / uL were subjected to Chromium Single Cell (10xGenomics) library
411	preparation and were sequenced on Illumina NextSeq 500. Cell Ranger Single-Cell Software Suite
412	(10X Genomics, v2.0.0) was used to perform sample de-multiplexing, alignment to MM10
413	Genome assembly with UCSC gene models, filtering, and UMI counting. PCA, UMAP and
414	clustering analyses used Seurat V3.2 (URLs) ⁷⁹ . Cluster marker genes as well as canonical cell type-
415	specific genes were used to manually label the cell type for each cluster.
416	
417	URLs
418	International Mouse Phenotyping Consortium: https://www.mousephenotype.org/.
419	gEAR portal: https://umgear.org/
420	GTEx: https://www.gtexportal.org/home/
421	[referred to in METHODS]
422	Mount Sinai BioMe: https://icahn.mssm.edu/research/ipm/programs/biome-biobank/pioneering
423	FinnGen: https://www.finngen.fi/
424	University of Michigan Imputation Server: https://imputationserver.sph.umich.edu/index.html
425	TOPMed Imputation Server: https://imputation.biodatacatalyst.nhlbi.nih.gov/
426	MakeScaffold: https://github.com/odelaneau/makeScaffold
427	SHAPEIT4: https://github.com/odelaneau/shapeit4
428	GTEx v8 eQTL data: https://www.gtexportal.org/

429 Seurat V3.2: https://github.com/satijalab/seurat

430

431 ACKNOWLEDGEMENTS

432 The authors would like to thank everyone who made this work possible. In particular: the UK 433 Biobank team, their funders, the dedicated professionals from the member institutions who 434 contributed to and supported this work, and most especially the UK Biobank participants, without 435 whom this research would not be possible. The exome sequencing was funded by the UK Biobank 436 Exome Sequencing Consortium (i.e., Bristol Myers Squibb, Regeneron, Biogen, Takeda, Abbvie, 437 Alnylam, AstraZeneca and Pfizer). This research has been conducted using the UK Biobank 438 Resource under application number 2604. We also want to acknowledge the participants and 439 investigators of the FinnGen study. We thank the MyCode Community Health Initiative 440 participants for taking part in the DiscovEHR collaboration.

441 Author contributions: All authors contributed to critical review of the manuscript for important442 intellectual content, and final approval of submission of the manuscript for publication.

- 443 Conceptualization: KP, EAS, MD, BZ, AB, GC
- 444 Data curation: MNC
- 445 Analysis: KP, LD, LG, MAF, AHA, JS, AP, AM, SC, EAS
- 446 Single-cell sequencing data generation and analysis: SM, YB, JS
- 447 Mouse experiments: AK
- 448 Project administration: EC, MJ

449 Datasets: OM

450 Supervision: MAF, GA, EAS, SB, BZ, GC, AB

451 Writing – original draft: KP, LD, EAS, GC

452 **Competing interests:**

453 Regeneron authors receive salary from and own options and/or stock of the company. Decibel454 authors receive salary and may own options and/or stock of the company.

455

457

456 Data availability statement

458 All whole-exome sequencing, genotyping chip, and imputed sequence for UKB described in this 459 report are publicly available to registered researchers via the UK Biobank data access protocol. 460 information about registration for access to the data is available Additional at 461 http://www.ukbiobank.ac.uk/register-apply/. Further information about the whole exome sequence 462 is available at http://www.ukbiobank.ac.uk/wp-content/uploads/2019/03/Access_064-UK-463 Biobank-50k-Exome-Release-FAQ-v3.pdf Detailed information about the chip and imputed 464 sequence is available at: http://www.ukbiobank.ac.uk/wp-content/uploads/2018/03/UKB-465 Genotyping-and-Imputation-Data-Release-FAQ-v3-2-1.pdf. Geisinger DiscovEHR, Malmo Diet 466 and Cancer study and Mt. Sinai Biome exome sequencing and genotyping data can be made 467 available to qualified, academic, non-commercial researchers upon request via a Data Transfer 468 Agreement with the respective institutions. Summary statistics for FinnGen r3 can be downloaded 469 from https://www.finngen.fi/en/access results.

FIGURES AND TABLES



Figure 1: Common (MAF \geq 0.01) variant (A), and rare (MAF < 0.01) coding single-variant and gene burden (B) associations with hearing loss. The gene labels refer to the nearest gene and colored in green are loci that have not previously been associated with hearing loss in the common variant results (A).

Table 1. Lead variants at the 15 novel loci associated with hearing loss. The alternate allele frequency (AAF) refers to the allele listed second in the 'Position' column. The direction of the effect in each single study (in the order: MALMO, UKB, GHS, SINAI, FinnGen) in the meta-analysis is given in the 'Direction' column where '+' indicates increased risk, '-' indicates decreased risk, and '?' indicates that the variant was not present or tested. The nSNPs column indicates the number of genome-wide significant SNPs within each locus.

Position	rsID	OR (LCI, UCI)	p-value	AAF	nSNPs	Nearest Gene	Direction
10:78760556:T:C	rs11596052	0.959 (0.947, 0.970)	7.14E-12	0.2162	94	ZMIZ1	+
12:109460927:A:G	rs1558804	1.033 (1.023, 1.044)	4.11E-11	0.4468	620	KCTD10	-+++
1:88282464:G:A	rs475788	1.036 (1.024, 1.047)	1.56E-10	0.7145	462	PKN2	-++++
23:152898837:T:C	rs186256023	1.082 (1.056, 1.109)	3.14E-10	0.0315	16	ZNF185	+++-?
21:42388983:C:T	rs45598239	1.070 (1.048, 1.093)	4.05E-10	0.0549	18	TMPRSS3	+++++
18:6678716:T:A	rs8090563	1.031 (1.021, 1.042)	4.29E-10	0.4901	210	ARHGAP28	+++++
20:62819980:C:T	rs61734651	1.062 (1.041, 1.083)	1.60E-09	0.0654	57	COL9A3	+++++
1:205751355:G:A	rs823116	0.971 (0.961, 0.980)	1.99E-09	0.5493	209	NUCKS1	+
23:20054286:C:T	rs7055595	1.033 (1.022, 1.044)	2.44E-09	0.2007	488	MAP7D2	++++?
11:69208057:T:C	rs7926098	1.030 (1.020, 1.041)	5.43E-09	0.6182	204	TPCN2	-++-+
13:20186225:A:T	rs117887149	1.114 (1.073, 1.156)	1.40E-08	0.0178	10	GJB2	+++-+
17:81711135:C:T	rs62077192	1.140 (1.089, 1.193)	1.55E-08	0.0117	92	SLC25A10	+++-+
8:73332501:T:C	rs4738323	1.035 (1.023, 1.048)	2.59E-08	0.1972	42	RDH10	-++++
16:55456852:T:A	rs17300627	0.967 (0.955, 0.978)	3.88E-08	0.2034	105	MMP2	+
23:116435671:G:A	rs3788766	1.025 (1.016, 1.034)	4.35E-08	0.6386	66	SLC6A14	+++-?

<u>Table 2:</u> Nonsynonymous rare (minor allele frequency, MAF < 0.01) variants and gene burdens associated ($P < 5 \times 10^{-8}$) with hearing loss in meta-analysis. The direction of the effect in each single study (in the order: MALMO, UKB, GHS, SINAI, FinnGen) in the meta-analysis is given in the 'Direction' column where '+' indicates increased risk, '-' indicates decreased risk and '?' indicates that the variant was not present or tested.

Gene	Top Burden/SNV	OR (LCI, UCI)	p-value	Direction
KLHDC7B	pLOF only (MAF ≤ 0.01)	2.145 (1.881, 2.446)	5.22E-30	-+++?
TECTA	pLOF + strict deleterious missense $(MAF \le 0.01)$	1.358 (1.271, 1.451)	1.10E-19	++++?
MYO6	pLOF + strict deleterious missense (MAF ≤ 0.0001)	1.565 (1.420, 1.725)	1.51E-19	+++??
FSCN2	pLOF + all missense (MAF ≤ 0.01)	1.144 (1.107, 1.183)	1.90E-15	+++-?
COL11A2	6:33189182:A:G; Phe80Ser	6.926 (4.280, 11.208)	3.24E-15	?+???
SYNJ2	6:158071628:C:T; Thr656Met	1.306 (1.221, 1.398)	1.25E-14	+++++
SLC26A5	pLOF and strict deleterious missense (MAF ≤ 0.0001)	1.956 (1.674, 2.284)	2.75E-17	-++??
СОСН	pLOF + strict deleterious missense (MAF \leq 0.0001)	1.719 (1.449, 2.039)	5.22E-10	-++??
SIX1	pLOF + strict deleterious missense (MAF ≤ 0.00001)	4.252 (2.825, 6.400)	3.95E-12	?++??
CEACAM16	pLOF + deleterious missense $(MAF \le 0.01)$	1.187 (1.128, 1.249)	4.01E-11	-++-?
GJB2	13:20189546:AC:A; Gly12fs	1.214 (1.146, 1.286)	4.23E-11	-+++?
TBC1D24	16:2497068:A:G; Asn307Ser	4.140 (2.571, 6.668)	5.10E-09	?++??
POU4F3	pLOF + all missense (MAF ≤ 0.00001)	1.923 (1.529, 2.418)	2.31E-08	?++??

CDH23	10:71712737:A:G; Asn1103Ser	1.204 (1.127, 1.287)	3.70E-08	++++?
EYA4	pLOF only $(MAF \le 0.001)$	3.077 (2.061, 4.595)	3.87E-08	+++??

A. GJB2 (Gly12fs)

Study	Cases	Controls	MAF						OR (LCI I UCI)	p-value
GHS	9,296 193 4	97,381 2,012 1	0.0105		H				1.10 (0.94 1.29)	2.5E-01
UKB	104,059 1,760 15	207,696 2,944 0	0.0075						1.24 (1.16 1.32)	1.6E–11
SINAI	307 7 0	9,857 163 0	0.0082	H	-				1.38 (0.57 3.35)	4.8E-01
MALMO	497 3 0	26,707 386 0	0.0070	H					0.54 (0.26 1.14)	1.0E-01
Meta	114,159 1,963 19	341,641 5,505 1	0.0081		•				1.21 (1.15 1.29)	4.2E-11
				- 1						
				0	1	2	3	4		
					OR	(95%	CI)			

Study	Cases	Controls	MAF						OR (LCI I UCI)	p-value
GHS	8,935 92 0	95,478 831 2	0.0044		+=-				1.15 (0.91 1.45)	2.5E-01
UKB	104,469 1,359 6	208,576 2,052 12	0.0054						1.32 (1.23 1.42)	2.2E-14
SINAI	312 2 0	9,940 82 0	0.0041	-	-				0.97 (0.24 4.00)	9.7E-01
MALMO	493 7 0	26,761 349 2	0.0063	H					1.19 (0.51 l 2.79)	6.9E-01
FinnGen	9,500 106 0	121,070 1,253 3	0.0016						1.09 (0.75 l 1.58)	6.6E-01
Meta	123,709 1,566 6	461,825 4,567 19	0.0052		•				1.30 (1.21 1.39)	3.1E-14
				0	1 OR	2 (95%	3 CI)	4		

B. SLC26A5 (Leu46Pro)

C. SLC26A5 aggregate of pLOF and strict deleterious missense

Study	Cases	Controls	MAF					OR (LCI I UCI)	p-value
GHS	9,002 25 0	96,103 208 0	0.0011					1.51 (0.92 2.47)	1.0E-01
UKB	98,267 307 0	195,806 330 0	0.0011		H			2.03 (1.73 2.40)	2.5E-17
MALMO	500 0 0	27,056 56 0	0.0010					NA	3.4E-01
Meta	107,769 332 0	318,965 594 0	0.0011		•			1.96 (1.67 2.28)	2.8E-17
				0	2	4	6		
					OR (95	5% CI)			

Figure 2: Association of *GJB2* Gly12fs (A), *SLC26A5* Leu46Pro (B) and *SLC26A5* pLOF

and strict deleterious missense, MAF \leq 0.0001 (C) with hearing loss.

A. *KLHDC7B* aggregate of predicted loss-of-function variants (MAF \leq 0.01)

Study	Cases	Controls	MAF						OR (LCI UCI)	p-value
GHS	8,998 29 0	96,149 162 0	0.0009	H	н				2.05 (1.32 3.19)	1.5E-03
UKB	98,123 451 0	195,687 449 0	0.0015	1	÷.,				2.15 (1.88 2.47)	9.3E-28
SINAI	313 1 0	10,007 11 0	0.0006	-			-	\rightarrow	14.26 (0.33 619.33)	1.7E-01
MALMO	500 0 0	27,092 20 0	0.0004						NA	5.7E-01
Meta	107,934 481 0	328,935 642 0	0.0013	•	•				2.14 (1.88 2.45)	5.2E-30
				F						
				0	5	10	15	20		
					OF	R (95%	CI)			

B. KLHDC7B (Lys181fs)

Study	Cases	Controls	MAF						OR (LCI UCI)	p-value
GHS	9,018 8 0	96,274 34 0	0.0002					4	2.90 (1.19 7.08)	1.9E-02
UKB	98,450 118 0	196,002 121 0	0.0004						2.14 (1.64 2.78)	1.9E-08
Meta	107,468 126 0	292,276 155 0	0.0004		-			-	2.19 (1.70 2.82)	1.4E-09
				0	2	4	6	8		
					OR	(95%	CI)			

C. KLHDC7B (Gly302fs)

Study	Cases	Controls	MAF					OR (LCI I UCI)	p-value
GHS	9,013 12 0	96,259 52 0	0.0003	•				2.69 (1.32 5.51)	6.6E-03
UKB	98,377 195 0	195,956 178 0	0.0006	•				2.34 (1.89 2.90)	6.9E-15
MALMO	313 1 0	10,013 9 0	0.0005	-	-		\rightarrow	49.78 (0.64 3,887.84)	7.9E-02
Meta	107,703 208 0	302,228 239 0	0.0005	•				2.39 (1.94 2.93)	9.5E-17
				-					
				0	50		100		
					OR (95%	5 CI)			

Figure 3: Association of rare variants in *KLHDC7B* with increased risk for hearing loss in meta-analysis. A. Association of an aggregate of predicted loss of function variants (MAF \leq 0.01) in *KLHDC7B* with risk for hearing loss. **B** and C. Two variants were the predominant contributors to the *KLHDC7B* loss-of-function gene burden aggregate, Lys181fs (B) and Gly302fs (C).

A. *FSCN2* aggregate of pLOF and missense (MAF \leq 0.01)

Study	Cases	Controls	MAF					OR (LCI UCI)	p-value
GHS	8,446 579 2	90,863 5,435 13	0.0287		•			1.15 (1.05 1.27)	2.6E-03
UKB	93,239 5,321 14	186,674 9,446 16	0.0252					1.14 (1.10 1.18)	4.8E-13
SINAI	299 15 0	9,436 579 3	0.0290		-			0.96 (0.57 1.63)	8.9E-01
MALMO	466 34 0	25,745 1,363 4	0.0254		-	-		1.43 (0.99 2.05)	5.7E-02
Meta	102,450 5,949 16	312,718 16,823 36	0.0261		•		-	1.14 (1.11 1.18)	1.9E-15
				- [Ι			
				0		2	4		



					OR	(95%	CI)			
B. <i>FSC</i>	CN2 (His138Tyr)									
Study	Cases	Controls	MAF						OR (LCI I UCI)	p-value
GHS	9,280 211 2	97,546 1,836 12	0.0095		H				1.21 (1.04 1.41)	1.6E-02
UKB	104,019 1,805 10	207,659 2,975 6	0.0076						1.24 (1.16 1.31)	1.2E-11
SINAI	179 3 0	4,832 109 1	0.0113	-	-				1.00 (0.27 3.65)	1.0E+00
MALMO	482 18 0	26,653 458 1	0.0087		-				2.22 (1.28 3.86)	4.8E-03
FinnGen	9,432 175 0	120,516 1,804 6	0.0082		HEH				1.24 (1.05 1.47)	1.2E-02
Meta	123,392 2,212 12	457,206 7,182 26	0.0080		•				1.24 (1.18 1.31)	4.1E-15
				-						
				0	1 OR	2 (95%	3 CI)	4		

C. SYNJ2 (Thr656Met)

Study	Cases	Controls	MAF					OR (LCI UCI)	p-value
GHS	9,362 130 1	98,229 1,162 3	0.0061		H			1.19 (0.97 1.46)	9.5E-02
UKB	97,319 1,238 17	194,164 1,969 3	0.0055		•			1.31 (1.22 1.41)	4.8E-13
SINAI	308 6 0	9,947 75 0	0.0039		-		\rightarrow	2.66 (1.00 7.04)	4.9E-02
MALMO	495 5 0	26,902 210 0	0.0039	F	-			1.26 (0.47 3.38)	6.5E-01
FinnGen	9,524 83 0	121,546 779 1	0.0022		H B -1			1.36 (0.97 1.92)	7.3E-02
Meta	117,008 1,462 18	450,788 4,195 7	0.0050		•		-	1.31 (1.22 1.40)	1.3E-14
				[
				0	2	4	6		
					OR (9	5% CI)			

Figure 4 Association of human hearing loss with genes previously implicated in hearing loss in mice. A. pLOF and missense (MAF ≤ 0.01) burden association in *FSCN2*. B. The His138Tyr variant is the major contributor to the burden. C. *SYNJ2* (Thr656Met) association with increased risk for hearing loss.



Minor Allele Frequency (MAF; log scale)

Figure 5: Effect size and allele frequency for variants associated with adult hearing loss. Plotted are odds ratio estimates (on log scale) and minor allele frequencies of genome-wide significant variants and gene burdens (Supplementary Tables 2, 6 & 7). 50% and 80% power curves for the present study are plotted as dotted lines. Notably, almost all points (particularly low-frequency and common variants, MAF > 0.0005) lie very close to the dotted power curves.

REFERENCES

- Cunningham, L. L. & Tucci, D. L. Hearing Loss in Adults. N. Engl. J. Med. 377, 2465–2473 (2017).
- National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy & Committee on Accessible and Affordable Hearing Health Care for Adults. *Hearing Health Care for Adults: Priorities for Improving Access and Affordability*. (National Academies Press, 2016).
- Livingston, G. *et al.* Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet* 396, 413–446 (2020).
- Morton, C. C. & Nance, W. E. Newborn hearing screening--a silent revolution. N. Engl. J. Med. 354, 2151–2164 (2006).
- 5. Korver, A. M. H. et al. Congenital hearing loss. Nat Rev Dis Primers 3, 16094 (2017).
- 6. Liberman, M. C. Noise-induced and age-related hearing loss: new perspectives and potential therapies. *F1000Res.* **6**, 927 (2017).
- Wu, P.-Z., O'Malley, J. T., de Gruttola, V. & Liberman, M. C. Age-related hearing loss is dominated by damage to inner ear sensory cells, not the cellular battery that powers them. *J. Neurosci.* 40, 6357–6366 (2020).
- 8. Karlsson, K. K., Harris, J. R. & Svartengren, M. Description and primary results from an audiometric study of male twins. *Ear Hear*. **18**, 114–120 (1997).
- Christensen, K., Frederiksen, H. & Hoffman, H. J. Genetic and environmental influences on self-reported reduced hearing in the old and oldest old. *J. Am. Geriatr. Soc.* 49, 1512–1517 (2001).
- Kvestad, E., Czajkowski, N., Krog, N. H., Engdahl, B. & Tambs, K. Heritability of hearing loss. *Epidemiology* 23, 328–331 (2012).

- Hendrickx, J.-J. *et al.* Familial aggregation of pure tone hearing thresholds in an aging European population. *Otol. Neurotol.* 34, 838–844 (2013).
- Viljanen, A. *et al.* Genetic and environmental influences on hearing in older women. J. *Gerontol. A Biol. Sci. Med. Sci.* 62, 447–452 (2007).
- Friedman, R. A. *et al.* GRM7 variants confer susceptibility to age-related hearing impairment. *Hum. Mol. Genet.* 18, 785–796 (2009).
- Hoffmann, T. J. *et al.* A Large Genome-Wide Association Study of Age-Related Hearing Impairment Using Electronic Health Records. *PLoS Genet.* 12, e1006371 (2016).
- 15. Nagtegaal, A. P. *et al.* Genome-wide association meta-analysis identifies five novel loci for age-related hearing impairment. *Sci. Rep.* **9**, 15192 (2019).
- 16. Fransen, E. *et al.* Genome-wide association analysis demonstrates the highly polygenic character of age-related hearing impairment. *Eur. J. Hum. Genet.* **23**, 110–115 (2015).
- Van Laer, L. *et al.* A genome-wide association study for age-related hearing impairment in the Saami. *Eur. J. Hum. Genet.* 18, 685–693 (2010).
- 18. Ivarsdottir, E. V. *et al.* The genetic architecture of age-related hearing impairment revealed by genome-wide association analysis. *Commun Biol* **4**, 706 (2021).
- Lewis, M. A. *et al.* Whole exome sequencing in adult-onset hearing loss reveals a high load of predicted pathogenic variants in known deafness-associated genes and identifies new candidate genes. *BMC Med. Genomics* 11, 77 (2018).
- 20. Tong, X. *et al.* Kctd10 regulates heart morphogenesis by repressing the transcriptional activity of Tbx5a in zebrafish. *Nat. Commun.* **5**, 3153 (2014).
- 21. Ren, K. *et al.* KCTD10 is involved in the cardiovascular system and Notch signaling during early embryonic development. *PLoS One* **9**, e112275 (2014).

- Pan, X. *et al.* MAP7D2 Localizes to the Proximal Axon and Locally Promotes Kinesin-1-Mediated Cargo Transport into the Axon. *Cell Rep.* 26, 1988-1999.e6 (2019).
- 23. Hanson-Kahn, A. *et al.* Autosomal recessive Stickler syndrome resulting from a COL9A3 mutation. *Am. J. Med. Genet. A* **176**, 2887–2891 (2018).
- Asamura, K., Abe, S., Fukuoka, H., Nakamura, Y. & Usami, S.-I. Mutation analysis of COL9A3, a gene highly expressed in the cochlea, in hearing loss patients. *Auris Nasus Larynx* 32, 113–117 (2005).
- 25. Wonkam, A., Manyisa, N., Bope, C. D., Dandara, C. & Chimusa, E. R. Whole Exome Sequencing Reveals Pathogenic Variants in MYO3A, MYO15A and COL9A3, and Differential Frequencies in Ancestral Alleles in Hearing Impairment Genes Among Individuals from Cameroon. *Hum. Mol. Genet.* (2020) doi:10.1093/hmg/ddaa225.
- 26. Dickinson, M. E. *et al.* High-throughput discovery of novel developmental phenotypes. *Nature* **537**, 508–514 (2016).
- Guipponi, M. *et al.* An integrated genetic and functional analysis of the role of type II transmembrane serine proteases (TMPRSSs) in hearing loss. *Hum. Mutat.* 29, 130–141 (2008).
- Fasquelle, L. *et al.* Tmprss3, a transmembrane serine protease deficient in human DFNB8/10 deafness, is critical for cochlear hair cell survival at the onset of hearing. *J. Biol. Chem.* 286, 17383–17397 (2011).
- Tang, P.-C. *et al.* Defective Tmprss3-associated hair cell degeneration in inner ear organoids. *Stem Cell Reports* 13, 147–162 (2019).

- Scott, H. S. *et al.* Insertion of beta-satellite repeats identifies a transmembrane protease causing both congenital and childhood onset autosomal recessive deafness. *Nat. Genet.* 27, 59–63 (2001).
- 31. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat. Genet.* **44**, 369–75, S1-3 (2012).
- 32. Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from genomewide association studies. *Bioinformatics* **32**, 1493–1501 (2016).
- Dobbyn, A. *et al.* Landscape of Conditional eQTL in Dorsolateral Prefrontal Cortex and Colocalization with Schizophrenia GWAS. *Am. J. Hum. Genet.* 102, 1169–1184 (2018).
- Shearer, A. E., Hildebrand, M. S. & Smith, R. J. H. Hereditary Hearing Loss and Deafness Overview. in *GeneReviews®* (eds. Adam, M. P. et al.) (University of Washington, Seattle, 1999).
- Mohiddin, S. A. *et al.* Novel association of hypertrophic cardiomyopathy, sensorineural deafness, and a mutation in unconventional myosin VI (MYO6). *J. Med. Genet.* 41, 309–314 (2004).
- 36. Street, V. A. *et al.* A novel DFNA9 mutation in the vWFA2 domain of COCH alters a conserved cysteine residue and intrachain disulfide bond formation resulting in progressive hearing loss and site-specific vestibular and central oculomotor dysfunction. *Am. J. Med. Genet. A* 139A, 86–95 (2005).
- Parzefall, T. *et al.* A Novel Variant in the TBC1D24 Lipid-Binding Pocket Causes Autosomal Dominant Hearing Loss: Evidence for a Genotype-Phenotype Correlation. *Front. Cell. Neurosci.* 14, 585669 (2020).

- Chakchouk, I. *et al.* Novel mutations confirm that COL11A2 is responsible for autosomal recessive non-syndromic hearing loss DFNB53. *Mol. Genet. Genomics* 290, 1327–1334 (2015).
- 39. Hashimoto, Y., Kim, D. J. & Adams, J. C. The roles of fascins in health and disease. *J. Pathol.*224, 289–300 (2011).
- 40. Perrin, B. J. *et al.* β-Actin and fascin-2 cooperate to maintain stereocilia length. *J. Neurosci.*33, 8114–8121 (2013).
- Liu, X. *et al.* Null Mutation of the Fascin2 Gene by TALEN Leading to Progressive Hearing Loss and Retinal Degeneration in C57BL/6J Mice. *G3* 8, 3221–3230 (2018).
- Rusk, N. *et al.* Synaptojanin 2 functions at an early step of clathrin-mediated endocytosis. *Curr. Biol.* 13, 659–663 (2003).
- 43. Manji, S. S. M. *et al.* A mutation in synaptojanin 2 causes progressive hearing loss in the ENU-mutagenised mouse strain Mozart. *PLoS One* **6**, e17607 (2011).
- 44. Martelletti, E. *et al.* Synaptojanin2 mutation causes progressive high-frequency hearing loss in mice. *Front. Cell. Neurosci.* **14**, 561857 (2020).
- 45. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat. Genet.* **47**, 1228–1235 (2015).
- Gazal, S. *et al.* Functional architecture of low-frequency variants highlights strength of negative selection across coding and non-coding annotations. *Nat. Genet.* 50, 1600–1607 (2018).
- Gong, R. *et al.* Hearing loss prevalence and risk factors among older adults in China. *Int. J. Audiol.* 57, 354–359 (2018).

- 48. Du, T.-T. *et al.* LMO7 deficiency reveals the significance of the cuticular plate for hearing function. *Nat. Commun.* **10**, 1117 (2019).
- 49. Liu, Y. et al. Critical role of spectrin in hearing development and deafness. Sci Adv 5, eaav7803 (2019).
- Lee, J. R. & White, T. W. Connexin-26 mutations in deafness and skin disease. *Expert Rev. Mol. Med.* 11, e35 (2009).
- 51. Kelsell, D. P. *et al.* Connexin 26 mutations in hereditary non-syndromic sensorineural deafness. *Nature* **387**, 80–83 (1997).
- 52. Kelley, P. M. *et al.* Novel mutations in the connexin 26 gene (GJB2) that cause autosomal recessive (DFNB1) hearing loss. *Am. J. Hum. Genet.* **62**, 792–799 (1998).
- 53. Rabionet, R. *et al.* Molecular basis of childhood deafness resulting from mutations in the GJB2 (connexin 26) gene. *Hum. Genet.* **106**, 40–44 (2000).
- Engel-Yeger, B. *et al.* The effects of a connexin 26 mutation--35delG--on oto-acoustic emissions and brainstem evoked potentials: homozygotes and carriers. *Hear. Res.* 163, 93–100 (2002).
- 55. Groh, D. *et al.* Hearing function in heterozygous carriers of a pathogenic GJB2 gene mutation. *Physiol. Res.* **62**, 323–330 (2013).
- 56. Mutai, H. *et al.* Diverse spectrum of rare deafness genes underlies early-childhood hearing loss in Japanese patients: a cross-sectional, multi-center next-generation sequencing study. *Orphanet J. Rare Dis.* 8, 172 (2013).
- 57. Liberman, M. C. *et al.* Prestin is required for electromotility of the outer hair cell and for the cochlear amplifier. *Nature* **419**, 300–304 (2002).

- Wells, H. R. R. et al. GWAS Identifies 44 Independent Associated Genomic Loci for Self-Reported Adult Hearing Difficulty in UK Biobank. Am. J. Hum. Genet. 105, 788–802 (2019).
- 59. Jeong, G. *et al.* A Kelch domain-containing KLHDC7B and a long non-coding RNA ST8SIA6-AS1 act oppositely on breast cancer cell proliferation via the interferon signaling pathway. *Sci. Rep.* **8**, 12922 (2018).
- Martín-Pardillos, A. & Cajal, S. R. Y. Characterization of Kelch domain-containing protein
 7B in breast tumours and breast cancer cell lines. *Oncol. Lett.* 18, 2853–2860 (2019).
- 61. Rudnicki, A. *et al.* Next-generation sequencing of small RNAs from inner ear sensory epithelium identifies microRNAs and defines regulatory pathways. *BMC Genomics* **15**, 484 (2014).
- Liu, H. *et al.* Cell-specific transcriptome analysis shows that adult pillar and Deiters' cells express genes encoding machinery for specializations of cochlear hair cells. *Front. Mol. Neurosci.* 11, 356 (2018).
- GTEx Consortium *et al.* Genetic effects on gene expression across human tissues. *Nature* 550, 204–213 (2017).
- Urbut, S. M., Wang, G., Carbonetto, P. & Stephens, M. Flexible statistical methods for estimating and testing effects in genomic studies with multiple conditions. *Nat. Genet.* 51, 187–195 (2019).
- 65. Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779 (2015).
- 66. Carey, D. J. *et al.* The Geisinger MyCode community health initiative: an electronic health record–linked biobank for precision medicine research. *Genet. Med.* **18**, 906–913 (2016).

- Berglund, G., Elmstähl, S., Janzon, L. & Larsson, S. A. The Malmo Diet and Cancer Study. Design and feasibility. *J. Intern. Med.* 233, 45–51 (1993).
- 68. Dewey, F. E. *et al.* Distribution and clinical impact of functional variants in 50,726 wholeexome sequences from the DiscovEHR study. *Science* **354**, aaf6814 (2016).
- Van Hout, C. V. *et al.* Exome sequencing and characterization of 49,960 individuals in the UK Biobank. *Nature* 586, 749–756 (2020).
- Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and binary traits. *Nat. Genet.* (2021) doi:10.1038/s41588-021-00870-7.
- 71. Girotto, G. *et al.* Hearing function and thresholds: a genome-wide association study in European isolated populations identifies new loci and pathways. *J. Med. Genet.* 48, 369–374 (2011).
- Nolan, L. S. *et al.* Estrogen-related receptor gamma and hearing function: evidence of a role in humans and mice. *Neurobiol. Aging* 34, 2077.e1–9 (2013).
- Wolber, L. E. *et al.* Salt-inducible kinase 3, SIK3, is a new gene associated with hearing. *Hum. Mol. Genet.* 23, 6407–6418 (2014).
- 74. Vuckovic, D. *et al.* Genome-wide association analysis on normal hearing function identifies
 PCDH20 and SLC28A3 as candidates for hearing function and loss. *Hum. Mol. Genet.* 24, 5655–5664 (2015).
- 75. Kalra, G. *et al.* Biological insights from multi-omic analysis of 31 genomic risk loci for adult hearing difficulty. *PLoS Genet.* e1009025 (2019) doi:10.1371/journal.pgen.1009025.
- Bulik-Sullivan, B. K. *et al*. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* 47, 291–295 (2015).

- 77. Staples, J. *et al.* PRIMUS: rapid reconstruction of pedigrees from genome-wide estimates of identity by descent. *Am. J. Hum. Genet.* **95**, 553–564 (2014).
- Delaneau, O., Zagury, J.-F., Robinson, M. R., Marchini, J. L. & Dermitzakis, E. T. Accurate, scalable and integrative haplotype estimation. *Nat. Commun.* 10, 5436 (2019).
- Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat. Biotechnol.* 36, 411–420 (2018).